You have 9 free searches left this month | to do more

acalabrutinib

Acalabrutinib is a drug used to treat Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, and other conditions. Acalabrutinib is being actively studied in 66 studies and prior, has been studied in 14.

Top SponsorsTop SitesTop Investigators
Acerta Pharma BVResearch SiteAustin I Kim
AstraZenecaM D Anderson Cancer CenterCarsten Utoft Niemann
M.D. Anderson Cancer CenterBeth Israel Deaconess Medical CenterCraig Moskowitz
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
Recruiting
  • Central Nervous System Lymphoma
  • Chapel Hill, North Carolina
  • +1 more
2022-03-24
Mar 24, 2022
W
Early Intervention With Acalabrutinib in Patients With High Risk CLL
Withdrawn
  • Chronic Lymphocytic Leukemia
  • CLL/SLL
  • Acalabrutinib
  • New York, New York
    Weill Cornell Medicine
2022-03-25
Mar 25, 2022
D
Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder
Recruiting
  • Post-transplant Lymphoproliferative Disorder
  • Cleveland, Ohio
    Cleveland Clinic, Case Comprehensive Cancer Center
2022-02-02
Feb 2, 2022
U
Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma
Not yet recruiting
  • Mantle Cell Lymphoma
  • (no location specified)
2021-08-04
Aug 4, 2021
D
Acalabrutinib in CNSL
Recruiting
  • Central Nervous System Lymphoma
  • +2 more
  • Acalabrutinib
  • Boston, Massachusetts
  • +1 more
2022-01-05
Jan 5, 2022
U
Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma
Recruiting
  • Mantle Cell Lymphoma
  • Acalabrutinib
  • R-CHOP chemotherapy
  • Vancouver, British Columbia, Canada
  • +3 more
2022-03-17
Mar 17, 2022
W
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Active, not recruiting
Has Results
  • Mantle Cell Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
2022-02-02
Feb 2, 2022
U
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Active, not recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Rochester, New York
    University of Rochester
2022-02-07
Feb 7, 2022
W
Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma
Recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
2022-03-14
Mar 14, 2022
F
Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease
Recruiting
  • Recurrent Moderate-Severe Chronic Graft Versus Host Disease
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Acalabrutinib
  • Questionnaire Administration
  • Tampa, Florida
  • +3 more
2021-12-22
Dec 22, 2021
C
Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
Recruiting
  • Autoimmune Hemolytic Anemia
  • +3 more
  • Acalabrutinib
  • Duarte, California
    City of Hope Medical Center
2022-03-09
Mar 9, 2022
A
A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants - 2020
Completed
  • Healthy Volunteers
  • Acalabrutinib
  • +2 more
  • Tempe, Arizona
    Celerion
2021-11-17
Nov 17, 2021
A
A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants - 2016
Completed
  • Healthy Volunteers
  • Tempe, Arizona
    Celerion
2021-06-02
Jun 2, 2021
S
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Recruiting
  • Diffuse Large B Cell Lymphoma
  • Seattle, Washington
    Swedish Cancer Institute
2021-03-01
Mar 1, 2021
M
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Acalabrutinib
  • Obinutuzumab
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-18
Nov 18, 2021
J
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +3 more
  • Acalabrutinib
  • Los Angeles, California
  • +2 more
2022-03-17
Mar 17, 2022
F
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Not yet recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-31
Mar 31, 2022
N
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Recruiting
  • Non-Hodgkin's Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
A
Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite - 2019
Completed
Has Results
  • Hepatic Impairment
  • +2 more
  • acalabrutinib
  • Miami, Florida
  • +2 more
2021-08-16
Aug 16, 2021
J
Preventing Anaphylaxis With Acalabrutinib
Recruiting
  • Food Allergy
  • Food Allergy Peanut
  • Acalabrutinib
  • Baltimore, Maryland
    Johns Hopkins Bayview Medical Center
2021-12-30
Dec 30, 2021
U
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Acalabrutinib
  • Axicabtagene Ciloleucel
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-16
Mar 16, 2022
N
Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Recruiting
  • Recurrent Follicular Lymphoma
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-12-16
Dec 16, 2021
J
ACALA-R In Anti-MAG Neuropathy Mediated Neuropathy
Recruiting
  • IgM MGUS
  • +2 more
  • Boston, Massachusetts
  • +1 more
2022-02-16
Feb 16, 2022
M
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Acalabrutinib
  • +4 more
  • Scottsdale, Arizona
  • +2 more
2021-08-19
Aug 19, 2021
S
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
Recruiting
  • Waldenstrom Macroglobulinemia
  • Acalabrutinib
  • +2 more
  • Vancouver, British Columbia, Canada
  • +3 more
2021-07-23
Jul 23, 2021